Market for Enzymatic Debridement set to surpass USD 1,549.2 million by 2034, recording a compound annual growth rate (CAGR) of 6.5%
The enzymatic debridement market is experiencing significant growth, with a compound annual growth rate (CAGR) of approximately 6.9% forecasted from 2024 to 2033 [1]. This growth is driven by a variety of factors, including the increased prevalence of chronic wounds, supportive government initiatives, and advances in wound care technologies.
In 2023, the market was valued at around USD 825.3 million, with chronic wounds accounting for a dominant market share of 73.3% [1]. By 2033, this market is projected to reach nearly USD 1,549.2 million [1]. The broader wound debridement products market, which includes enzymatic methods, was valued at approximately USD 5.0 billion in 2025 and is expected to reach about USD 9.7 billion by 2035 [1].
One of the key benefits of enzymatic debridement is its less invasive and effective nature compared to other methods. This makes it an attractive option in the field of wound care.
In North America, the enzymatic debridement market holds a dominant position, generating revenues of USD 392.0 million in 2023 [1]. Companies like DeRoyal, with their JetoxTM ND Jet Lavage Wound Cleansing & Debridement System, are contributing to this growth [2]. This system initiates thorough cleansing using compressed air/oxygen combined with a minimal amount of standard sterile solution.
Other notable players in the market include Arobella Medical, specializing in low-frequency cavitational ultrasound technology for wound care, and Colloplast, providing Purilon® Gel, a hydrogel used for wounds requiring effective and gentle debridement of necrotic tissue [3][4].
Advancis Medical has introduced AdvaGel and AdvaGel Ag, hydrocolloid dressings designed to enhance wound healing by maintaining a moist environment and facilitating autolytic debridement [5]. Meanwhile, B. Braun offers the Prontosan® Debridement Pad, intended to support the soft mechanical debridement of chronic wounds [6].
In the realm of bioactive and nanotechnology-based therapies, products like ConvaTec's AQUACEL® EXTRATM Hydrofiber® dressing and Lohmann & Rauscher's Hydrosorb® Gel, a hydrogel dressing that facilitates autolytic debridement, are making waves in the market [7][8].
The United States and Canada continue to lead in adopting advanced treatment modalities in the enzymatic debridement market. Based on end-use, hospitals represented the leading segment with a 54.3% market share in 2023 [1].
EZ Debride offers a single-use, disposable instrument designed for sharp debridement of topical wounds, while Integra LifeSciences offers MediHoney® Wound & Burn Dressing, which contains Active Leptospermum (Manuka) Honey [9][10]. Mölnlycke Healthcare offers Mepitel® One, a silicone wound contact layer that facilitates autolytic debridement [11].
Collagenase-based solutions led the market with a 56.4% share in 2023 [1]. Collagenase is derived from both microbial and animal sources.
As the enzymatic debridement market continues to evolve, it's clear that advancements in wound care technologies are playing a crucial role in improving patient outcomes.
[1] Market Research Report (2023) [2] DeRoyal (2023) [3] Coloplast (2023) [4] Mölnlycke Healthcare (2023) [5] Advancis Medical (2023) [6] B. Braun (2023) [7] ConvaTec (2023) [8] Lohmann & Rauscher (2023) [9] EZ Debride (2023) [10] Integra LifeSciences (2023)
- In the field of health and wellness, enzymatic debridement, with its less invasive and effective nature, proves to be particularly useful in managing medical-conditions like chronic wounds and chronic diseases.
- The United States and Canada, known for adopting advanced treatment modalities, are leading in the research and application of science, particularly in the arena of enzymatic debridement for chronic diseases and medical-conditions.
%20of%206.5%25){kind=link}